Aperiomics Names Robb Milne Director of Sales and Marketing

Ashburn, VA – August 1, 2017 —Aperiomics, a biotechnology company that saves lives by harnessing the power of next-generation sequencing to identify any known pathogen (bacteria, virus, fungi or parasite) in a single test, today announced that Robb Milne has joined the company as Director of Sales and Marketing.
Milne brings to Aperiomics more than 20 years of success as a sales leader, his perspective establishing synergy between the high-tech and biotech industries. He is tasked with taking Aperiomics to the next level of success and increasing visibility so the company can help more people worldwide. Most recently, he guided creation of the company’s new website, an information portal for clinicians, patients and researchers.

Robb Milne

Over his career, Milne has been ranked a top sales executive at a number of high tech companies including Logi Analytics, ApeSoft and Sage. He also serves as a member of the Northern Virginia Technology Council, VirginiaBio and the Northern Virginia Chamber of Commerce.

“We’re very excited to have someone with Robb’s strong experience and skills on the team,” said company CEO Crystal Icenhour. “As we move forward, he is in charge of expanding our reach to all of our audiences including the medical industry and patients themselves using a wide variety of media and methods. The services that Aperiomics provides are unique in the world and the faster we get word out about them, the more people we will be able to help.”

Milne holds a bachelor of arts degree in communications/public relations from George Mason University in Fairfax, VA, and has completed training with a number of nationally recognized sales organizations including Dale Carnegie Sales Advantage, Xerox Document University Sales, the Sandler High-Tech Selling System Training and Skip Miller’s Proactive Sales Training.

About Aperiomics
Aperiomics is the only company identifying every bacteria, DNA virus, fungi or parasite in one test. Clinicians and patients call on Aperiomics to identify infectious diseases that other tests cannot identify. The only company of its kind and scope in the world, Aperiomics identifies every known pathogen (bacteria, virus, fungi or parasite) in a single test through next-generation sequencing of the DNA or RNA in any sample (patient, environmental, etc.). The complete genetic fingerprint of that sample is then compared to the Aperiomics Microbial Database™- the most comprehensive database of microorganisms, including the world’s largest collection of pathogens. This breakthrough is only possible through Aperiomics and can be used to identify unknown/chronic infections, limit the use of antibiotics and solve difficult medical cases. Patients and their families often contact Aperiomics directly after hearing about their successes in helping others. Aperiomics was named Life Sciences Innovators of the year in 2016 and as a finalist in the 2017 Greater Washington Innovation Awards.